BC
BCRX icon

Bridgefront Capital’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bridgefront Capital’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-40,889
Closed -$389K – 521
2026
Q1 		$389K Buy
+40,889
New +$318K 0.1% 323
2025
Q4 		– Sell
-23,650
Closed -$180K – 533
2025
Q3 		$180K Sell
23,650
-19,329
-45% -$161K 0.05% 528
2025
Q2 		$385K Buy
+42,979
New +$400K 0.1% 350
2024
Q4 		– Sell
-33,126
Closed -$252K – 584
2024
Q3 		$252K Buy
33,126
+20,212
+157% +$154K 0.1% 385
2024
Q2 		$79.8K Buy
+12,914
New +$71.3K 0.03% 456
2023
Q4 		– Sell
-16,323
Closed -$116K – 382
2023
Q3 		$116K Sell
16,323
-3,979
-20% -$28.6K 0.08% 350
2023
Q2 		$143K Buy
+20,302
New +$163K 0.08% 407
2021
Q2 		– Sell
-20,028
Closed -$204K – 613
2021
Q1 		$204K Buy
+20,028
New +$207K 0.06% 583

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Bridgefront Capital's BCRX Position: Q2 2026 in Review

Bridgefront Capital sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2026, closing a stake of 40,889 shares — an estimated $389K sold.

Bridgefront Capital first reported a position in BCRX in Q1 2021 and held it in 8 quarters. The position peaked at $389K in Q1 2026. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Bridgefront Capital reported no remaining BioCryst Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Bridgefront Capital sold 40,889 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $389K.
  • Bridgefront Capital first reported a position in BioCryst Pharmaceuticals in Q1 2021 and held it in 8 quarters.
  • Bridgefront Capital's BioCryst Pharmaceuticals position peaked at $389K in Q1 2026.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Bridgefront Capital's 13F filing for Q2 2026, filed 14 Aug 2026.